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Adequate HPC collection is critical for patients under-
going AHPCT. HPC mobilization is usually done with G-CSF,
which affects the stromal derived factor-1a interaction with
HPC. Other adhesion molecules also play a role in HPC
mobilization e.g. very late antigen-4 (VLA-4) expressed on
HPCs, and its ligand, vascular cell adhesion molecule-1,
expressed on the bone marrow microenvironment. Borte-
zomib, a proteasome inhibitor, has been shown to down
regulate VLA-4. In this study, bortezomib was used with
G-CSF to mobilize and collect HPC for AHPCT. Sixteen
patients (11 males), aged 42 e 70 years, with MM (n¼9) or
NHL (n¼7,) undergoing AHCPT for the ﬁrst time, were
enrolled after obtaining consent. Patients with >grade II
neuropathy or platelet count <100K/ml were excluded.
Bortezomib was administered on days -11 and -8 at a dose of
1.3mg/m2 iv, followed by G-CSF 10mg/kg sc, on days -4 to -1
prior to HPC collection (day 0). Results were compared with
matched patients with MM or NHL undergoing AHPCT at our
Institution. All patients had CD34+ cell enumeration from the
peripheral blood on the day of collection, and followed
a published Institutional algorithm regarding the use of
plerixafor. If the CD34+ cell count was adequate, patients
underwent a high volume HPC collection, if the CD34+ count
was <5/ml, then they received plerixafor. In this study, one
patient (6%) had CD34+ cell count of 3.9/ml on day 0 and
received plerixafor, as compared to 33% of matched historical
controls. Botezomibr was well tolerated and all patients had
adequate HPC collections with no mobilization failures. 10
patients completed HPC collection in one day and 7 in two
days. All patients had timely neutrophil and platelet
engraftment post AHPCT. Bortezomib + G-CSF is an effective
HPC mobilizing regimen worth investigating in subsequent
studies. Bortezomib also has known anti MM and NHL
effects.127
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Background: In a recent phase IIa open-label, randomized,
cross-over design study, we evaluated the pharmacokinetics
of Propylene Glycol-Free Melphalan (PG-free Mel) HCL and
Alkeran in multiple myeloma patients undergoing trans-
plantation. In this study, we have shown through statistical
tests of the geometric means of AUC that PG-free Mel was
bioequivalent to Alkeran, and provided marginally higher
blood drug levels.
Hypothesis: Because this new formulation is associated with
marginally higher blood drug levels and because melphalan
is associated with a linear dose-response curve, we specu-
lated that patients treated on study would have a better
multiple myeloma response compared to matched controls.
Goal: To assess day +100 multiple myeloma responses from
the study patients (N¼24) receiving PG-free Mel condi-
tioning in combination with Alkeran. Responses were
assessed based on International Uniform Response Criteria
for Multiple Myeloma. Comparison was made to a matched
cohort of patients who received conventional melphalan.
Methods: We compared the study patient responses to
matched controls (N¼24) treated exclusively with Alkeran or
generic melphalan conditioning within the same time frame
in a case-control study design. The controls were matched to
study population based on disease stage, age, and pre-
transplant response.
Results: The study population and the control cohort were
well matched in terms of age, gender, disease stage, and pre-
transplant response. However, the study population had
higher-risk cytogenetics (10 vs 3). Overall response (CR,
VGPR, and PR) was higher in the study population (22 vs 19).
While no patient on the study progressed within 100 days of
transplant, 3 patients in the matched cohort progressed
within 100 days. After a median follow up of 650 days in the
study patients and 409 days in the control cohort, 23 patients
on the study and 22 patients in the matched cohort were
reported alive. Seven patients on the study, while 8 patients
in the matched cohort progressed during follow up.
Conclusion: Compared to matched controls, PG-free Mel, as
part of the melphalan conditioning regimen, achieved higher
remission rates and less disease progression at day 100 post
autologous transplant for multiple myeloma.
128
BEAM or ICE?
Fevzi Altuntas, Sinem civriz Bozdag, Itir Demiriz, Aysegul Tetik,
Omur Kayikci, Murat Cinarsoy, Sinem Namdaroglu, Bilge Ugur,
Emre Tekgunduz. Ankara Oncology Hospital
Introduction: High dose chemotherapy and autologous
hematopoietic stem cell transplantation (AHSCT) has been
widely used in the treatment of relapsed/refractory patients.
As there are a few randomized studies comparing the
conditioning regimens in AHSCT, we aim to analyze the
transplant outcomes of the patients who has been treated
with BEAM or ICE regimens.
Patients-Method: We included sixty eight Hodgkin/Non
Hodgkin lymphoma patients, who had been transplanted in
our Bone Marrow Transplantation Unit between 2010-2012.
Demographic features of the patients are summarized in
